United Therapeutics is making a major strategic bet on xenotransplantation and bioengineered organs as its primary long-term growth driver. The is using genetically modified pig organs to reduce rejection risk — with its UHeart and UKidney programmes having already achieved transplants in living humans. In parallel, it is developing 3D-bioprinted lungs, livers and kidneys using human cells, and pursuing decellularization techniques through its Miromatrix subsidiary, all aimed at addressing the global shortage of transplantable organs.
Management has outlined regulatory submissions targeted for 2028 and possible commercialisation by 2029–2030. Significant investment is going into designated pathogen-free manufacturing facilities to enable organ production at scale.